Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment

In 855 Japanese patients with type 2 diabetes receiving once weekly dulaglutide 0.75 mg in 3 phase 3 studies, the effects on efficacy and safety at week 26 (last observation carried forward) were investigated in a post hoc descriptive analysis of subgroups of age (

Saved in:
Bibliographic Details
Published in:Endocrine Journal 2017, Vol.64(4), pp.449-456
Main Authors: Hamano, Kumiko, Nishiyama, Hiroshi, Matsui, Akiko, Sato, Manaka, Takeuchi, Masakazu
Format: Article
Language:English
Subjects:
Adult
Age
Age Factors
Aged
Aging - physiology
Asian Continental Ancestry Group
Body Mass Index
Body weight
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
Dulaglutide
Female
Follow-Up Studies
Geriatrics
GLP-1 receptor agonist
Glucagon-Like Peptides - adverse effects
Glucagon-Like Peptides - analogs & derivatives
Glucagon-Like Peptides - therapeutic use
Hemoglobin
Humans
Hypoglycemia
Immunoglobulin Fc Fragments - adverse effects
Immunoglobulin Fc Fragments - therapeutic use
Japan
Male
Middle Aged
Nausea
Patients
Recombinant Fusion Proteins - adverse effects
Recombinant Fusion Proteins - therapeutic use
Subgroup analysis
Treatment Outcome
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 855 Japanese patients with type 2 diabetes receiving once weekly dulaglutide 0.75 mg in 3 phase 3 studies, the effects on efficacy and safety at week 26 (last observation carried forward) were investigated in a post hoc descriptive analysis of subgroups of age (
ISSN:0918-8959
1348-4540
DOI:10.1507/endocrj.EJ16-0428